Table 4.
Overview of iron oxide nanoparticles/drugs and their applications
| Nanoparticles | Drugs/targeting agent | Applications | References |
|---|---|---|---|
| Magnetic mesoporous silica gated with doped carbon dot | 5-FU | Fluorescence imaging of Sla-overexpressed HePG2 cancer cells | 103 |
| Magnetic iron oxide/mesoporous silica nanocomposites (m-MCM-41) | 5-FU | Drug release system | 104 |
| Chitosan-co-PEG/poly(glycerol sebacate)-co-PEG-coated iron oxide | 5-FU | Carrier for 5-FU anticancer, HT29 cell line | 105 |
| Polylactic-co-glycolic acid (PLGA) NPs as 5-FU carriers with/without iron oxide core | 5-FU | Carrier for 5-FU anticancer human colon cancer cell line HT29 | 106 |
| PLGA-coated magnetite nanographene oxide | 5-FU | Rabbit plasma | 107 |
| Polycaprolactone (PCL)/chitosan (CHI)-coated superparamagnetic iron oxide nanographene oxide (SPION-NGO) | 5-FU | CT26 colon cancer cell line | 108 |
| Magnetic NPs Fe3O4 | 5-FU | 7,901 cancer cells | 119 |
| Magnetic field-sensitive methylcellulose and PCL gels | 5-FU | Targeted and controlled release | 110 |
| B-cyclodextrin–PEG–polyethyleneimine-coated iron oxide NPs | 5-FU | L929 and MCF-7 | 111 |
| Encapsulation of superparamagnetic Fe3O4 | 5-FU | 7,901 cancer cells | 112 |
| Polyglycerol-coated iron oxide NPs | FA | Human cervical carcinoma cell line | 113 |
| Magnetic mesoporous silica NPs | FA | Cancerous HeLa cells | 114 |
| Folate-decorated cobalt ferrite nanoparticles coated with PEG | FA | HSF 1184 (human skin fibroblast cells) and HeLa (human cervical cancer cell, FAR+) | 115 |
| Iron oxide NPs/hyperbranched polyglycerol | FA | MCF-7 cells | 116 |
| Iron oxide NP-conjugated chitosan-graft-poly(2-dimethylaminoethyl methacrylate) | FA | L929 (mouse fibroblast) cell line, MCF-7 (human breast cancer) cell line, and MDA-MB-231 (human breast cancer) cell line | 117 |
| Iron oxide NPs | FA | MRI detection and hyperthermia treatment of lymph node metastases of prostate cancer | 118 |
| Magnetite@SiO2 nanostructures | FA | Human cervical cancer line | 119 |
| Aminosilane MNPs | FA | Colorectal cancer and an animal model of cancer xenograft | 120 |
| Magnetic NPs/PEG | FA | Human cervix epitheloid carcinoma HeLa cells, human breast carcinoma cells MCF-7 and MDA-MB435 | 121 |
| Starch/ZnO-coated iron oxide NPs | FA | Human lymphocytes, HepG2, and MCF-7 cell lines | 122 |
| Fe3O4-ZnO hybrid NPs | FA | Photodynamic therapy, human epithelial colorectal adenocarcinoma (Caco-2) cells | 123 |
| Poly(N-isopropylacrylamide) hydrogel core/superparamagnetic magnetite NPs | FA | Cervical cancer cell line (HeLa) | 124 |
| Polyethylenimine superparamagnetic iron oxide NPs | FA | MRI and PD-L1 siRNA delivery for gastric cancer | 125 |
| Iron oxide NPs/functionalized with FA and rhodamine | FA | Cell proliferation assay on HeLa cells | 126 |
| Bovine serum albumin-coated superparamagnetic γ-Fe2O3 NPs | FA | U251 | 127 |
| Amine group immobilized iron oxides, Fe3O4-NH2, attached on the surface of self-assembled triblock copolymer, poly[(acrylic acid)-block-(N-isopropylacrylamide)-block-(acrylic acid)] | FA | MCF-7 | 128 |
| Basic cobalt ferrite (CoFe2O4) particles covalently bonded with a photosensitizer | FA | PC-3 | 129 |
| Carboxylated quercetin conjugated to superparamagnetic iron oxide NPs modified by (3-aminopropyl) triethoxysilane, FA, and carboxylated PEG | FA | MCF-7, HeLa, and A549 | 130 |
| Superparamagnetic iron oxide functionalized with (3-aminopropyl) triethoxysilane and PEG | FA | U87 | 131 |
| Superparamagnetic iron oxide NPs coated with chitosan and FA-conjugated chitosan | FA | MCF-7 | 132 |
| FA-targeted iron oxide (Fe3O4) NPs | FA | Human serous ovarian cell line (Skov-3) | 133 |
| Iron oxide NPs/chitosan, FA/loaded with aqueous poorly soluble quercetin | FA | PC-3 and MCF-7 | 134 |
| Magnetic mesoporous silica NPs/CuS nanocrystals/photothermal agent/PEG | FA | HeLa | 135 |
| PEGylated PEG bis(carboxymethyl ether)/Fe3O4 NPs | DOX | Cancer therapy | 136 |
| Fe3O4@MoS2 nanocubes | DOX | Human breast cancer xenograft in nude mice | 137 |
| DOX-loaded dendritic-Fe3O4 supramolecular NPs | DOX | Magnetic drug targeting and tumor regression in spheroid murine melanoma model | 138 |
| PEGylated cubic Fe3O4 NPs | DOX | Mouse skin fibrosarcoma (WEHI-164) cells | 139 |
| Magnetite NPs hydrophilized by nonionic surfactant pluronic F127–polyethylene-polypropylene oxide polymer | DOX | LNCaP and PC-3 prostate cancer cell lines | 140 |
| Chitosan-functionalized Fe3O4 NPs | DOX | Ovarian cancer cell (SK-OV-3) and breast cancer cell line (MCF-7) | 141 |
| Fe3O4 NPs coated with poly(N-isopropylacrylamide) | DOX | Human cervical carcinoma cell line, MRI | 142 |
| Iron oxide NPs/DOX-loaded calcium phosphate/arginylglycylaspartic acid | DOX | T24 bladder cancer cells | 143 |
| Sodium alginate-polyvinyl alcohol-bovine serum albumin-coated Fe3O4 NPs | DOX | HepG2 and L02 cells | 144 |
| FA-conjugated PEG-coated MNPs | DOX | HeLa cell line | 145 |
| Fe3O4-inositol hexaphosphate | DOX | MG-63 cell line | 146 |
| Genipin-cross-linked iron (III) oxide/polyetherimide NPs | DOX | HeLa cell line | 147 |
| Polyvinyl alcohol hydrogel grafted by modified Fe3O4 NPs | DOX | DOX delivery | 148 |
| Cucurbit[7]uril-modified iron-oxide NPs | DOX | HeLa cells, MCF-7, A2780, Dox-resistant A2780, and HEK293 cells | 149 |
| Dextran-coated superparamagnetic iron oxide NPs | DOX | Human pancreatic carcinoma cell lines MIA PaCa-2 | 150 |
| Dual-targeted NPs loaded with DOX and MNPs | DOX | MCF-7 | 151 |
| Superparamagnetic iron oxide NPs | DOX | LO2 and HepG2 | 152 |
| Liposome-capped core-shell mesoporous silica-coated superparamagnetic iron oxide NPs | DOX | MCF-7 and U87 | 153 |
| Fe3O4 NP-capped mesoporous silica | DOX | HepG2 | 154 |
| Superparamagnetic Fe3O4 NPs | DOX | L929 and HeLa | 155 |
| Azobis[N-(2-carboxyethyl)–2-methylpropionamidine] | DOX | MCF-7 | 156 |
| Superparamagnetic iron oxide NPs | DOX | U251 | 157 |
| Iron oxide@meso-silica NPs | DOX | HeLa cell line | 158 |
| Polyacrylic acid-functionalized Fe3O4 NPs are conjugated with FA through peptide bonding | DOX | HeLa cell line | 159 |
| Fe3O4 encapsulated in inner aqueous phase and hydrophobic drug (curcumin) | DOX | HeLa cell line | 160 |
| PEG carboxyl–poly(ε-caprolactone)-modified MNPs | PTX | Mouse H22 hepatocarcinoma cells (H22), human embryonic kidney cells (HEK293T), and hepatoma carcinoma cell (Hep G2) | 161 |
| Loaded magnetic NPs modified with methoxy PEG-lysine-oleic acid | PTX | Liver, left kidney, and right kidney cell | 162 |
| Fe3O4⋅dopamine-bovine serum albumin/hyaluronic acid | PTX | MRI | 163 |
| TAT peptide-conjugated magnetic PLA-PEG nanocapsules | PTX | Human lung adenocarcinoma epithelial cells A549 | 164 |
| Peptide H7K(R2)2-modified, theranostic liposome-superparamagnetic iron oxide NPs | PTX | H7K(R2)2 in MDA-MB-231 cell line, MRI | 165 |
| Fe3O4 NPs into porous isoreticular metal | PTX | HeLa and NIH3T3 | 166 |
| Methoxy PEG-poly(d, l-lactide-co-glycolide)(MPEG-PLGA) | PTX | HeLa and A549 | 167 |
| Superparamagnetic polymer microcontainers | Dau | pH-sensitive controlled release mechanism | 168 |
| Dau-loaded MNPs | Dau | Human chronic myelogenous leukemia cells (K562 cells) | 169 |
| Magnetic iron oxide NPs coloaded with Dau and 5-bromotetrandrin | Dau | Human leukemia K562/A02 cells | 170 |
| PLA multiwalled carbon nanotubes Fe3O4 composite nanofibers | Dau | Leukemia cancer cells | 171 |
| ZnFe2O4 NPs | Dau | HeLa cells | 172 |
Abbreviations: Dau, Daunorubicin; DOX, doxorubicin; 5-FU, 5-fluorouracil; FA, folic acid; FAR, folic acid receptor; MNPs, magnetic nanoparticles; NPs, nanoparticles; PEG, polyethylene glycol; PLA, polylactic acid; PTX, paclitaxel.